ARTICLE | Clinical News
Copaxone glatiramer acetate: Phase III data
September 29, 2008 7:00 AM UTC
In a 15-year follow-up of an open-label extension of 100 patients from a Phase III trial of Copaxone to treat RRMS, 57% of patients experienced either stabilized or improved disease (<=0.5 point chang...